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Abstract Diva is a novel proapoptotic member of the Bcl-2
protein family which binds apoptosis activating factor-1 (APAF-
1). Diva is identical with Boo which was identified as a novel
antiapoptotic Bcl-2 family protein. Here, we report that Diva
promotes the cell cycle exit of human glioma cells in response to
serum deprivation and inhibits apoptosis of these cells induced by
CD95 ligand or chemotherapeutic drugs. In glioma cells, Diva
interferes with apoptotic signaling downstream of cytochrome c
release, but upstream of caspase activation, consistent with an
inhibitory effect on the mitochondrial amplification step invol-
ving the apoptosome and APAF-1. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Gene transfer-mediated antisense inhibition of the expres-
sion of antiapoptotic Bcl-2 family members, or overexpression
of proapoptotic Bcl-2 family members, are promising thera-
peutic strategies for cancers which are resistance to radioche-
motherapy-induced apoptosis. Of the four Bcl-2 homology
domains BH1^BH4, BH3 has been identi¢ed as the essential
domain for proapoptotic Bcl-2 homologs to interact with the
principal antiapoptotic family members, Bcl-2 and Bcl-XL,
and to induce apoptosis [1]. Diva (death inducer binding to
vBcl-2 and apoptosis-activating factor, APAF-1) was identi-
¢ed as a proapoptotic member of the Bcl-2 family that ap-
peared not to require the BH3 domain for the induction of
apoptosis [2]. Instead, Diva was hypothesized to inhibit the
association of Bcl-XL and APAF-1 via direct interactions with
APAF-1, thereby antagonizing the antiapoptotic activity of
Bcl-XL. Diva mRNA was abundantly expressed in embryonal
tissues including brain, but was restricted to ovary and testis
in adult mice. Diva is identical with Boo (Bcl-2 homolog of
ovary) which was characterized as an antiapoptotic Bcl-2 ho-
molog interacting with APAF-1 [3].
2. Materials and methods
2.1. Materials and cell lines
Lomustine (CCNU) was obtained from Medac (Hamburg, Ger-
many), DEVD-amc from Bachem (Heidelberg, Germany). CD95L-
containing supernatant was harvested from CD95L-transfected N2A
neuroblastoma cells [4]. The human malignant glioma cell lines LN-
18, U138MG, U87MG, LN-428, D247MG, T98G, LN-319, LN-229,
A172, U251MG, U373MG and LN-308 were kindly provided by N.
de Tribolet (Lausanne, Switzerland). The cells were maintained in
Dulbecco’s modi¢ed Eagle’s medium (Gibco Life Technologies,
Eggenstein, Germany) containing 10% fetal calf serum, glutamine
(2 mM) and penicillin (100 IU/ml)/streptomycin (100 Wg/ml). Trans-
fections were done by lipofection with pcDNA3 as a control (mock)
or pcDNA3-myc-Diva, kindly provided by G. Nunez (Ann Arbor,
MI, USA). Pooled stably transfected sublines were generated by se-
lection with G418 (50 Wg/ml). Transient transfections were done by
lipofection with pcDNA3neo or pcDNA3-myc-Diva in combination
with pEGFP encoding enhanced green £uorescent protein to assess
the e⁄cacy of transfection.
2.2. Immunoblot analysis
The general procedure has been described [5]. The following anti-
bodies were used: anti-myc (9E10, Santa Cruz SC40, Santa Cruz, CA,
USA); anti-actin (1-19, Santa Cruz SC1616); anti-cytochrome c
(65981A, Pharmingen-Becton Dickinson, Heidelberg, Germany);
anti-caspase 3 (#C31720, Transduction Laboratories, Lexington,
KY, USA); anti-caspase 8 (kindly provided by P.H. Krammer, Hei-
delberg, Germany).
2.3. Proliferation and viability assays
For acute drug cytotoxicity assays, the cells were seeded at 104 cells
per well in microtiter plates, allowed to attach for 24 h and exposed to
CD95L for 24 h or cancer chemotherapy drugs for 72 h in serum-free
medium. Viable cells were stained by crystal violet. For transient
transfections, cell death was measured by £ow cytometry, counting
sub-G0/1 double-transfected neo/EGFP- or Diva-EGFP-positive cells.
2.4. Cell cycle analysis
The cells were seeded in 75 cm2 £asks and allowed to attach. The
cells were washed twice with phosphate-bu¡ered saline (PBS) and then
serum-deprived for up to 96 h. Detached cells were harvested from the
supernatant by centrifugation and added to the non-detached cells
harvested by trypsinization. The cells were washed with PBS, ¢xed
in 70% ice-cold ethanol, centrifuged, washed with PBS, and 106 cells
per condition were stained with propidium iodide (50 Wg/ml) diluted in
PBS containing RNase A (100 Wg/ml). The cells were subjected to £ow
cytometric analysis of DNA content using a Becton Dickinson FACS-
calibur cytometer. Percentages of cells in the di¡erent cell cycle phases
were calculated by CellQuest software (Becton Dickinson).
2.5. DEVD-amc cleaving caspase activity assay
The cells (104) were seeded on microtiter plates, allowed to attach
for 24 h and then treated with CD95L. At 0, 3 and 6 h after CD95L
exposure, the cells were lysed in 25 mM Tris^HCl, pH 8.0, 60 mM
NaCl, 2.5 mM EDTA, 0.25% Nonidet-P40 for 10 min, and DEVD-
amc was added at 12.5 WM. Caspase activity was assessed by £uores-
cence using a Millipore £uorimeter at 360 nm excitation and 480 nm
emission wave lengths [6].
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Fig. 1. Diva promotes growth arrest in response to serum deprivation. A: LN-18 glioma cells were transfected with the empty vector (mock)
or pcDNA-myc-Diva. Transgene expression was assessed by immunoblot using the anti-myc antibody. The upper unspeci¢c band serves as a
loading control. B: LN-18 mock (open circles) or Diva-transfected (¢lled circles) LN-18 cells were seeded on microtiter plates, allowed to at-
tach, and serum-deprived for up to 120 h. Growth was assessed by cresyl violet staining. C: Cell cycle analysis of LN-18 mock and Diva-ex-
pressing LN-18 cells was performed at various time points after serum deprivation.
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3. Results
The present study was performed to assess whether Diva
acted as a proapoptotic or an antiapoptotic gene in human
malignant glioma cells. Northern blot analysis revealed that
Diva/Boo mRNA was not expressed constitutively in any of
12 human malignant glioma cell lines (data not shown). LN-
18 glioma cells were transfected by lipofection with a
pcDNA3-myc-tagged Diva plasmid. Pooled polyclonal sub-
lines stably expressing Diva were selected in medium contain-
ing G418 (50 Wg/ml) for 6^8 weeks. To avoid artifacts from
clonal selection, all experiments were performed with pooled
Fig. 2. Diva inhibits CD95L- and CCNU-induced apoptosis in glioma cells. A: Mock (open bars) or Diva-transfected (black bars) LN-18 cells
were treated with increasing concentrations of CD95L (upper panel) or CCNU (lower panel) for 72 h. Survival was measured by cresyl violet
staining. Note the logarithmic increase in concentration to assess the degree of protection mediated by Diva (*P6 0.05, t-test). B: LN-18
mock- or Diva-transfected cells were treated with CD95L (30 U/ml) for 0 (open bars), 3 (gray bars) or 6 h (black bars). Caspase activity was
assessed by £uorescence (*P6 0.05, t-test). C^F: LN-18 mock- or Diva-transfected cells were treated with CD95L (25 U/ml). Protein levels and
caspase cleavage were assessed by immunoblot using (C) anti-caspase 8; (D) anti-caspase 3; (E) anti-cytochrome c or, as a loading control,
(F) L-actin antibody.
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transfected LN-18 sublines. Stable transgene expression was
con¢rmed by immunoblot using an antibody to the myc tag of
transgenic Diva protein (Fig. 1A). There was no e¡ect of
ectopic Diva expression on the doubling times (Diva-trans-
fected LN-18 cells, 16.5 þ 1 h; mock-transfected LN-18 cells,
18 þ 0.5 h) or on the clonogenicity (Diva-transfected LN-18
cells, 13.2%; mock-transfected LN-18 cells, 12.8%), as as-
sessed by colony formation assays. However, Diva-transfected
cells were more sensitive to serum deprivation-induced growth
arrest. In contrast to parental LN-18 cells (not shown) and
mock-transfected LN-18 cells which continued to grow in se-
rum-free medium, Diva-transfected LN-18 cells no longer pro-
liferated under these conditions (Fig. 1B). Flow cytometric
cell cycle analysis revealed that neither mock- nor Diva-trans-
fected cells died in the time frame of the experiments, but that
Diva-transfected cells, in contrast to mock-transfected cells,
arrested in G0/1 in response to serum deprivation (Fig. 1C).
Thus, 77% of Diva-expressing cells were found in G0/1, com-
pared with 28% in the control transfectants, at 96 h of serum
deprivation.
Diva-transfected cells were also assessed for a modulation
of sensitivity to apoptosis. Fig. 2A shows that Diva-trans-
fected cells were more resistant to the induction of apoptosis
mediated by CD95L and the nitrosourea CCNU than mock-
transfected cells. Similar data were obtained for the topo-
isomerase II inhibitor, teniposide (VM26) (data not
shown). Protection from apoptosis mediated by Diva was
consistently found in di¡erent sublines of Diva-transfected
LN-18 cells.
The Diva-mediated protection from CD95L-induced apo-
ptosis was associated with reduced DEVD-amc cleaving cas-
pase activity (Fig. 2B). Further, the CD95L-evoked processing
of caspases 8 and 3 was reduced in the Diva-transfected LN-
18 cells at 3 and 6 h (Fig. 2C,D). Reduced caspase 8 process-
ing is re£ected by the prevention of caspase 8/p18 formation.
Reduced caspase 3 processing becomes apparent from the
prevention of loss of the 30 kDa full length caspase 3. The
protection mediated by Diva in the DEVD-amc cleavage as-
say at 3 h (Fig. 2B), a time point where no major caspase 3
processing became apparent by immunoblot analysis (Fig.
2D), indicates that the enzyme assay is more sensitive than
immunoblot analysis and probably re£ects the early activation
of caspases other than caspase 3. Interestingly, the release of
cytochrome c was not prevented by Diva at 3 h, but was
instead less sustained since almost no more cytochrome c
release was detected at 6 h in Diva-transfected LN-18 cells
(Fig. 2E).
4. Discussion
The previous studies yielded con£icting results regarding
the modulation of apoptosis by Diva. Transient Diva trans-
fection induced cell death in 293T kidney cells, Ramsey mel-
anoma cells and T47D breast cancer cells [2]. Conversely,
stable expression of Boo inhibited cyclosporine-, irradiation-
and interleukin 3 deprivation-induced apoptosis of the FL5.12
prolymphocytic cell line and the bone marrow-derived Baf-3
cell line [3].
The present study de¢nes an antiapoptotic e¡ect of Diva/
Boo in stably transfected human glioma cells treated with
CD95L or CCNU (Fig. 1). In contrast to previous observa-
tions in other cell types [2], there was no proapoptotic e¡ect of
Diva upon treatment with CD95L or CCNU in transient
transfection assays assessed up to 48 h after transfection
(data not shown).
The failure of Diva to prevent the initial cytochrome c
release evoked by CD95L is consistent with the hypothesis
that Diva acts at the level of the apoptosome to modulate
apoptosis [2,3]. At least in the paradigms examined here,
Diva appeared to prevent the e⁄cient triggering of the caspase
cascade by the apoptosome. That fact that caspase 8 process-
ing was inhibited by Diva in the glioma cells is consistent with
our previous observation of insu⁄cient processing of caspase
8 at the death-induced signaling complex during CD95-medi-
ated apoptosis [7] : although caspase 8 is thought to be the
most apical caspase activated by CD95L, a mitochondrial
ampli¢cation step is required to promote e⁄cient caspase 8
processing. Accordingly, Bcl-2 and Bcl-XL also inhibit
CD95L-induced caspase 8 processing, but, in contrast to
Diva, Bcl-2 and Bcl-XL also block mitochondrial cytochrome
c release, and thus act at a level upstream of the action of
Diva.
The present study identi¢ed a second, presumably inde-
pendent e¡ect of Diva expressed in glioma cells. Diva pro-
moted the exit from the cell cycle in glioma cells in response
to serum deprivation. Similar results have been obtained in
Bcl-2-transfected FDC-P1 cells, an interleukin 3-dependent
mouse promyelomonocytic cell line [8], and Bcl-2 transgenic
mouse thymocytes [9]. The physiological role of antiapoptotic
Bcl-2 family proteins mediating cell cycle exit under unfavor-
able growth conditions remains to be identi¢ed.
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